

Supplemental Online Content

Domalpally A, Whittier SA, Pan Q, et al; for the Diabetes Prevention Program Research (DPPOS) Group. Association of metformin with the development of age-related macular degeneration. *JAMA Ophthalmol*. Published online December 22, 2022. doi:10.1001/jamaophthalmol.2022.5567

eTable 1. Comparison of AMD severity status evaluated from color photographs and SDOCT

eTable 2. Distribution of number of years of metformin use by AMD severity

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1: Comparison of AMD severity status evaluated from color photographs and SDOCT. Agreement between the two modalities was 93%. The kappa statistic was 0.79.

Color Photography AMD	SDOCT AMD				
	absent/ questionable	early AMD	intermediate AMD	Geographic atrophy	Neovascular AMD
Absent/ questionable	2390	0	0	6	3
early AMD	133	228	0	1	1
intermediate AMD	58	0	244	7	4
Geographic atrophy	0	0	0	4	4
Neovascular AMD	0	0	0	0	9

eTable 2: Distribution of number of years of metformin use by AMD severity. There was no difference in the number of years of metformin use between the AMD severity levels.

Characteristics	P-value		Absent (n=1108)	Early AMD (n=229)	Intermediate AMD (n=218)	Advanced AMD (n=32)	Overall (n=1592)
Years with any metformin	0.81	Mean(SD) Median(IQR)	7.75(7.68) 5.5(0,14.50)	7.30(7.60) 5.0(0,13.00)	7.55(7.71) 5.5(0,14.00)	6.99(8.01) 3.5(0,12.75)	7.67(7.68) 5.5(0,14.00)
Years with in-study metformin	0.97	Mean(SD) Median(IQR)	4.38(7.47) 0(0, 6.38)	4.27(7.48) 0(0, 5.50)	4.22(7.25) 0(0, 6.50)	3.96(7.72) 0(0, 2.88)	4.35(7.45) 0(0, 6.25)
Years with out of study metformin	0.51	Mean(SD) Median(IQR)	3.40(4.75) 0(0, 6.50)	3.06(4.39) 0(0, 6.00)	3.35(5.11) 0(0, 6.50)	3.11(4.32) 0(0.50,5.50)	3.34(4.74) 0(0, 6.50)